ZyVersa Therapeutics (Nasdaq: ZVSA, or “ZyVersa”), a
clinical-stage specialty biopharmaceutical company developing
first-in-class drugs for treatment of renal and inflammatory
diseases, highlights an article published in the peer-reviewed
Journal of Translational Medicine supporting that NLRP3 activation
is associated with a pathologic inflammatory response in obese
children with insulin resistance and increased risk of developing
metabolic complications. Inflammation and oxidative stress, which
are closely related pathophysiological processes, one of which can
be easily induced by the other, are key drivers for developing
metabolic complications, such as type 2 diabetes and cardiovascular
disease, in this population.
In the paper titled, “Altered insulin secretion dynamics relate
to oxidative stress and inflammasome activation in children with
obesity and insulin resistance,” the authors conducted a
case-controlled study of 132 children who were either lean or
obese. The obese group was segmented into those with or without
insulin resistance, and those with insulin resistance were
segmented into those with an early and late insulin response to
glucose as determined by an oral glucose tolerance test (OGTT).
The researchers reported the following key findings in Children
with obesity, insulin resistance, and increased risk of metabolic
complications:
- Higher levels of NLRP3 and its effector proteins (active IL-1β,
caspase-1, and gasdermin D) in peripheral blood mononuclear cells
(PBMCs) and serum compared to the other groups studied, indicative
of NLRP3 activation and an inflammatory response.
- Higher levels of uric acid versus the other groups, a
well-known trigger of NLRP3 activation.
- Increased levels of oxidative stress and oxidative damage
versus the other groups.
The authors concluded, “It is insulin response to an OGTT that
identifies children with obesity suffering oxidative stress, and
inflammasome activation more specifically. Uric acid could be
mediating this pathological inflammatory response by activating
NLRP3 in peripheral blood mononuclear cells.”
To read the article, Click Here.
“Childhood obesity, which has increased more than 8-fold over
the last 40 years, is an alarming health problem today due to the
increased risk for developing type 2 diabetes, early heart disease,
and other co-morbidities,” commented Stephen C. Glover, ZyVersa’s
Co-founder, Chairman, CEO, and President. “The research published
in the Journal of Translational Medicine points to a significant
role for inflammasome-mediated inflammation and oxidative stress in
development of metabolic complications in obese children. ZyVersa
is developing Inflammasome ASC Inhibitor IC 100 designed to inhibit
NLRP3 and other types of inflammasomes and their associated ASC
specks to attenuate initiation and perpetuation of inflammation,
which may have therapeutic potential to alleviate metabolic
complications of childhood obesity with early intervention.”
To review a white paper summarizing the mechanism of action and
preclinical data for IC 100, Click Here.
About Inflammasome ASC Inhibitor IC 100
IC 100 is a novel humanized IgG4 monoclonal antibody that
inhibits the inflammasome adaptor protein ASC. IC 100 was designed
to attenuate both initiation and perpetuation of the inflammatory
response. It does so by binding to a specific region of the ASC
component of multiple types of inflammasomes, including NLRP1,
NLRP2, NLRP3, NLRC4, AIM2, Pyrin. Intracellularly, IC 100 binds to
ASC monomers, inhibiting inflammasome formation, thereby blocking
activation of IL-1β early in the inflammatory cascade. IC 100 also
binds to ASC in ASC Specks, both intracellularly and
extracellularly, further blocking activation of IL-1β and the
perpetuation of the inflammatory response that is pathogenic in
inflammatory diseases. Because active cytokines amplify adaptive
immunity through various mechanisms, IC 100, by attenuating
cytokine activation, also attenuates the adaptive immune
response.
About ZyVersa Therapeutics, Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty
biopharmaceutical company leveraging advanced, proprietary
technologies to develop first-in-class drugs for patients with
renal and inflammatory diseases who have significant unmet medical
needs. The Company is currently advancing a therapeutic development
pipeline with multiple programs built around its two proprietary
technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment
of kidney diseases, and Inflammasome ASC Inhibitor IC 100,
targeting damaging inflammation associated with numerous CNS and
other inflammatory diseases. For more information, please visit
www.zyversa.com.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this press release regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These include statements regarding
management’s intentions, plans, beliefs, expectations, or forecasts
for the future, and, therefore, you are cautioned not to place
undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional
financing.
New factors emerge from time-to-time, and it is not possible for
ZyVersa to predict all such factors, nor can ZyVersa assess the
impact of each such factor on the business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Forward-looking statements included in this press
release are based on information available to ZyVersa as of the
date of this press release. ZyVersa disclaims any obligation to
update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, any securities.
Corporate and IR Contact:Karen CashmereChief
Commercial
Officerkcashmere@zyversa.com786-251-9641
Media ContactsTiberend Strategic Advisors,
Inc.Casey McDonaldcmcdonald@tiberend.com646-577-8520
Dave Schemeliadschemelia@tiberend.com609-468-9325
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Aug 2024 to Sep 2024
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Sep 2023 to Sep 2024